INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ biologic therapy (e.g., bevacizumab) as part of    │ biologic therapy (e.g., bevacizumab) as part of    │     100 │
│ their primary treatment regimen or part of their   │ their primary treatment regimen or part of their   │         │
│ treatment for management of recurrent or           │ treatment for management of recurrent or           │         │
│ persistent disease                                 │ persistent disease                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Histologic documentation of the original primary   │ Histologic documentation of the original primary   │     100 │
│ tumor                                              │ tumor                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Documented radiographic disease progression \< 12  │ Documented radiographic disease progression < 12   │     100 │
│ months after the last dose of first- or second-    │ months after the last dose of first- or second-    │         │
│ line platinum-based chemotherapy                   │ line platinum-based chemotherapy                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemoglobin: ≥ 9 g/dL                               │ Hemoglobin: ≥ 9 g/dL                               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum bilirubin: ≤ 1.2 mg/dL                       │ Serum bilirubin: ≤ 1.2 mg/dL                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Alkaline phosphatase: ≤ 2.5 x ULN                  │ Alkaline phosphatase: ≤ 2.5 x ULN                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age ≥18 years                                      │ Age ≥18 years                                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Able and willing to give valid written informed    │ Able and willing to give valid written informed    │     100 │
│ consent                                            │ consent                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with platinum-refractory disease, defined │ Subjects with platinum-refractory disease, defined │     100 │
│ as disease progression while receiving first line  │ as disease progression while receiving first line  │         │
│ platinum-based therapy                             │ platinum-based therapy                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically significant persistent immune-related   │ Clinically significant persistent immune-related   │     100 │
│ adverse events following prior therapy             │ adverse events following prior therapy             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Myocardial infarction or unstable angina within 6  │ Myocardial infarction or unstable angina within 6  │     100 │
│ months prior to Day 1 of the study                 │ months prior to Day 1 of the study                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of serious ventricular arrhythmia (i.e.,   │ History of serious ventricular arrhythmia (i.e.,   │     100 │
│ ventricular tachycardia or ventricular             │ ventricular tachycardia or ventricular             │         │
│ fibrillation) or cardiac arrhythmias requiring     │ fibrillation) or cardiac arrhythmias requiring     │         │
│ anti-arrhythmic medications, except for atrial     │ anti-arrhythmic medications, except for atrial     │         │
│ fibrillation that is well controlled with anti-    │ fibrillation that is well controlled with anti-    │         │
│ arrhythmic medication                              │ arrhythmic medication                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of pneumonitis or interstitial lung        │ History of pneumonitis or interstitial lung        │     100 │
│ disease                                            │ disease                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active, suspected or prior documented autoimmune   │ Active, suspected or prior documented autoimmune   │     100 │
│ disease (including inflammatory bowel disease,     │ disease (including inflammatory bowel disease,     │         │
│ celiac disease, Wegner's granulomatosis, active    │ celiac disease, Wegner's granulomatosis, active    │         │
│ Hashimoto's thyroiditis, rheumatoid arthritis,     │ Hashimoto's thyroiditis, rheumatoid arthritis,     │         │
│ lupus, scleroderma and its variants, multiple      │ lupus, scleroderma and its variants, multiple      │         │
│ sclerosis, myasthenia gravis). Vitiligo, type I    │ sclerosis, myasthenia gravis). Vitiligo, type I    │         │
│ diabetes mellitus, residual hypothyroidism due to  │ diabetes mellitus, residual hypothyroidism due to  │         │
│ autoimmune condition only requiring hormone        │ autoimmune condition only requiring hormone        │         │
│ replacement, psoriasis not requiring systemic      │ replacement, psoriasis not requiring systemic      │         │
│ treatment, or conditions not expected to recur in  │ treatment, or conditions not expected to recur in  │         │
│ the absence of an external trigger were permitted  │ the absence of an external trigger are permitted   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other malignancy within 2 years prior to Day 1 of  │ Other malignancy within 2 years prior to Day 1 of  │     100 │
│ the study, except for those treated with surgical  │ the study, except for those treated with surgical  │         │
│ intervention only                                  │ intervention only                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with clinical symptoms or signs of        │ Subjects with clinical symptoms or signs of        │     100 │
│ gastrointestinal obstruction and/or who required   │ gastrointestinal obstruction and/or who require    │         │
│ drainage gastrostomy tube and/or parenteral        │ drainage gastrostomy tube and/or parenteral        │         │
│ hydration or nutrition                             │ hydration or nutrition                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of severe allergic reactions to any        │ History of severe allergic reactions to any        │     100 │
│ unknown allergens or components of the study drugs │ unknown allergens or components of the study drugs │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other serious illnesses (e.g., serious infections  │ Other serious illnesses (e.g., serious infections  │     100 │
│ requiring antibiotics, bleeding disorders)         │ requiring antibiotics, bleeding disorders)         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior treatment in any other interventional        │ Prior treatment in any other interventional        │     100 │
│ clinical trial within 4 weeks prior to Day 1 of    │ clinical trial within 4 weeks prior to Day 1 of    │         │
│ the study                                          │ the study                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Lack of availability for immunological and         │ Lack of availability for immunological and         │     100 │
│ clinical follow-up assessment                      │ clinical follow-up assessment                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of allogeneic organ transplant             │ History of allogeneic organ transplant             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Resistant hypertension                             │ Resisted hypertension                              │      88 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects must not have donated blood while on      │ Subjects must not donate blood while on study and  │      89 │
│ study and for at least 90 days following the last  │ for at least 90 days following the last MEDI4736   │         │
│ durvalumab treatment                               │ treatment                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects must have had recurrent or persistent     │ Subjects must have recurrent or persistent         │      94 │
│ platinum-resistant epithelial ovarian, fallopian   │ platinum-resistant epithelial ovarian, fallopian   │         │
│ tube, or primary peritoneal carcinoma with         │ tube, or primary peritoneal carcinoma with         │         │
│ measurable disease (as defined by the Response     │ measureable disease (as defined by RECIST 1.1.)    │         │
│ Evaluation Criteria in Solid Tumors \[RECIST\]     │ after first or second line platinum-based          │         │
│ 1.1.) after first or second line platinum-based    │ chemotherapy, for which treatment with PLD is      │         │
│ chemotherapy, for which treatment with PLD was     │ indicated. Platinum-based therapy is defined as    │         │
│ indicated. Platinum-based therapy was defined as   │ treatment with carboplatin, cisplatin or another   │         │
│ treatment with carboplatin, cisplatin or another   │ organoplatinum compound. Platinum-resistant is     │         │
│ organoplatinum compound. Platinum-resistant was    │ defined as having a platinum-free interval (PFI)   │         │
│ defined as having a platinum-free interval of \<   │ of < 12 months after first- or second-line         │         │
│ 12 months after first- or second-line platinum-    │ platinum-based chemotherapy, or having disease     │         │
│ based chemotherapy, or having disease progression  │ progression while receiving second-line platinum-  │         │
│ while receiving second-line platinum-based         │ based chemotherapy                                 │         │
│ chemotherapy                                       │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum creatinine: ≤ 1.5 x institutional upper      │ Serum creatinine, ≤ 1.5x Institutional Upper Limit │      94 │
│ limit of normal (ULN), or creatinine clearance ≥   │ of Normal (ULN), or Creatinine Clearance ≥ 50      │         │
│ 50 mL/min (by Cockcroft-Gault formula)             │ mL/min (by Cockcroft-Gault formula)                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with history or evidence upon physical    │ Subjects with history or evidence upon physical    │      94 │
│ examination of central nervous system disease,     │ examination of CNS disease, including primary      │         │
│ including primary brain tumor, seizures not        │ brain tumor, seizures not controlled with standard │         │
│ controlled with standard medical therapy, any      │ medical therapy, any brain metastases, or, within  │         │
│ brain metastases, or, within 6 months prior to Day │ six months prior to Day 1 of this study, history   │         │
│ 1 of this study, history of cerebrovascular        │ of cerebrovascular accident (CVA, stroke),         │         │
│ accident (stroke), transient ischemic attack or    │ transient ischemic attack (TIA) or subarachnoid    │         │
│ subarachnoid hemorrhage                            │ hemorrhage                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ New York Heart Association Class II or higher      │ New York Heart Association (NYHA) Class II or      │      95 │
│ congestive heart failure                           │ higher congestive heart failure                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects were allowed to have received, but were   │ Subjects are allowed to have received, but are not │      96 │
│ not required to have received                      │ required to have received                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects in Phase 2 must have had disease amenable │ Subjects in Phase 2 must have disease amenable to  │      96 │
│ to biopsy and must have been willing to undergo    │ biopsy and must be willing to undergo pre- and     │         │
│ pre- and post-treatment tumor biopsies. Optional   │ post-treatment tumor biopsies. Optional for Phase  │         │
│ for Phase 1                                        │ 1                                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Note: archival tissue was requested for all        │ Note: archival tissue will be requested for all    │      97 │
│ subjects preferably from primary tumor site prior  │ subjects preferably from primary tumor site prior  │         │
│ to cancer treatment; however, archival tissue was  │ to cancer treatment; however, archival tissue is   │         │
│ not a requirement for study entry                  │ not a requirement for study entry                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Laboratory parameters for vital functions should   │ Laboratory parameters for vital functions should   │      97 │
│ have been in the normal range. Laboratory          │ be in the normal range. Laboratory abnormalities   │         │
│ abnormalities that were not clinically significant │ that are not clinically significant are generally  │         │
│ were generally permitted, except for the following │ permitted, except for the following laboratory     │         │
│ laboratory parameters, which must have been within │ parameters, which must be within the ranges        │         │
│ the ranges specified, regardless of clinical       │ specified, regardless of clinical significance     │         │
│ significance                                       │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Neutrophil count: ≥ 1.5 x 10\^9/L                  │ Neutrophil count: ≥ 1.5 x 109/L                    │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Platelet count: ≥ 100,000/mm\^3                    │ Platelet count: ≥ 100,000/mm3                      │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Body weight \> 30 kg                               │ Body weight > 30 kg                                │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Mental impairment that may have compromised        │ Mental impairment that may compromise compliance   │      97 │
│ compliance with the requirements of the study      │ with the requirements of the study                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any condition that, in the clinical judgment of    │ Any condition that, in the clinical judgment of    │      98 │
│ the treating physician, was likely to prevent the  │ the treating physician, is likely to prevent the   │         │
│ subject from complying with any aspect of the      │ subject from complying with any aspect of the      │         │
│ protocol or that may have put the subject at       │ protocol or that may put the subject at            │         │
│ unacceptable risk                                  │ unacceptable risk                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with clinically significant               │ Subjects with clinically significant               │      99 │
│ cardiovascular disease. This included              │ cardiovascular disease. This includes              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Grade 2 or higher peripheral ischemia, except for  │ Grade 2 or higher peripheral ischemia, except for  │      99 │
│ brief (\< 24 hours) episodes of ischemia managed   │ brief (< 24 hrs) episodes of ischemia managed non- │         │
│ non-surgically and without permanent deficit       │ surgically and without permanent deficit           │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must be FEMALE                                     │ Serum bilirubin: ≤ 1.2 mg/dL                       │      24 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females \< 50 years of age were considered post-   │ Subjects must have recurrent or persistent         │      39 │
│ menopausal if they had been amenorrheic for 12     │ platinum-resistant epithelial ovarian, fallopian   │         │
│ months or more following cessation of exogenous    │ tube, or primary peritoneal carcinoma with         │         │
│ hormonal treatments and if they had luteinizing    │ measureable disease (as defined by RECIST 1.1.)    │         │
│ hormone and follicle-stimulating hormone levels in │ after first or second line platinum-based          │         │
│ the post-menopausal range for the institution or   │ chemotherapy, for which treatment with PLD is      │         │
│ underwent surgical sterilization (bilateral        │ indicated. Platinum-based therapy is defined as    │         │
│ oophorectomy or hysterectomy)                      │ treatment with carboplatin, cisplatin or another   │         │
│                                                    │ organoplatinum compound. Platinum-resistant is     │         │
│                                                    │ defined as having a platinum-free interval (PFI)   │         │
│                                                    │ of < 12 months after first- or second-line         │         │
│                                                    │ platinum-based chemotherapy, or having disease     │         │
│                                                    │ progression while receiving second-line platinum-  │         │
│                                                    │ based chemotherapy                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women of childbearing potential who were found to  │ Note: archival tissue will be requested for all    │      40 │
│ be pregnant as evidenced by positive serum         │ subjects preferably from primary tumor site prior  │         │
│ pregnancy test (minimum sensitivity 25 IU/L or     │ to cancer treatment; however, archival tissue is   │         │
│ equivalent units of human chorionic gonadotropin)  │ not a requirement for study entry                  │         │
│ or nursing. NOTE: Pregnancy tests were not         │                                                    │         │
│ required for subjects who were not of childbearing │                                                    │         │
│ potential as defined in #17                        │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females ≥ 50 years of age were considered post-    │ Subjects must have recurrent or persistent         │      40 │
│ menopausal if they had been amenorrheic for 12     │ platinum-resistant epithelial ovarian, fallopian   │         │
│ months or more following cessation of all          │ tube, or primary peritoneal carcinoma with         │         │
│ exogenous hormonal treatments, had radiation-      │ measureable disease (as defined by RECIST 1.1.)    │         │
│ induced menopause with last menses \> 1 year ago,  │ after first or second line platinum-based          │         │
│ had chemotherapy-induced menopause with last       │ chemotherapy, for which treatment with PLD is      │         │
│ menses \> 1 year ago, or underwent surgical        │ indicated. Platinum-based therapy is defined as    │         │
│ sterilization (bilateral oophorectomy, bilateral   │ treatment with carboplatin, cisplatin or another   │         │
│ salpingectomy or hysterectomy)                     │ organoplatinum compound. Platinum-resistant is     │         │
│                                                    │ defined as having a platinum-free interval (PFI)   │         │
│                                                    │ of < 12 months after first- or second-line         │         │
│                                                    │ platinum-based chemotherapy, or having disease     │         │
│                                                    │ progression while receiving second-line platinum-  │         │
│                                                    │ based chemotherapy                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female subjects of childbearing potential who were │ Subjects must have recurrent or persistent         │      41 │
│ sexually active with a nonsterilized male partner  │ platinum-resistant epithelial ovarian, fallopian   │         │
│ must have used at least one highly effective       │ tube, or primary peritoneal carcinoma with         │         │
│ method of contraception from screening, and must   │ measureable disease (as defined by RECIST 1.1.)    │         │
│ have agreed to continue using such precautions for │ after first or second line platinum-based          │         │
│ 90 days after the final dose of investigational    │ chemotherapy, for which treatment with PLD is      │         │
│ product (durvalumab). Male partners of a female    │ indicated. Platinum-based therapy is defined as    │         │
│ subject must have used male condom plus spermicide │ treatment with carboplatin, cisplatin or another   │         │
│ throughout this period (from screening and for 90  │ organoplatinum compound. Platinum-resistant is     │         │
│ days after subject's receipt of the final dose of  │ defined as having a platinum-free interval (PFI)   │         │
│ investigational product). Cessation of birth       │ of < 12 months after first- or second-line         │         │
│ control after this point should have been          │ platinum-based chemotherapy, or having disease     │         │
│ discussed with a responsible physician. Not        │ progression while receiving second-line platinum-  │         │
│ engaging in sexual activity for the total duration │ based chemotherapy                                 │         │
│ of the trial and the drug washout period was an    │                                                    │         │
│ acceptable practice; however, periodic abstinence, │                                                    │         │
│ the rhythm method, and the withdrawal method were  │                                                    │         │
│ not acceptable methods of birth control            │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ NOTE: For the standard of care, PLD (Doxil®,       │ Note: archival tissue will be requested for all    │      41 │
│ Caelyx®), the package insert advises females of    │ subjects preferably from primary tumor site prior  │         │
│ reproductive potential to use effective            │ to cancer treatment; however, archival tissue is   │         │
│ contraception during and for 6 months after last   │ not a requirement for study entry                  │         │
│ treatment with the drug. Therefore, all subjects   │                                                    │         │
│ of childbearing potential on this study should     │                                                    │         │
│ have continued contraception use for 6 months      │                                                    │         │
│ after the last PLD administration                  │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females of childbearing potential were defined as  │ biologic therapy (e.g., bevacizumab) as part of    │      42 │
│ those who were not surgically sterile (i.e.,       │ their primary treatment regimen or part of their   │         │
│ bilateral tubal ligation, bilateral oophorectomy,  │ treatment for management of recurrent or           │         │
│ or complete hysterectomy) or post-menopausal       │ persistent disease                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females were considered post-menopausal if they    │ Note: archival tissue will be requested for all    │      42 │
│ had been amenorrheic for 12 months without an      │ subjects preferably from primary tumor site prior  │         │
│ alternative medical cause. The following age-      │ to cancer treatment; however, archival tissue is   │         │
│ specific requirements applied                      │ not a requirement for study entry                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A highly effective method of contraception was     │ Active, suspected or prior documented autoimmune   │      42 │
│ defined as one that results in a low failure rate  │ disease (including inflammatory bowel disease,     │         │
│ (i.e., less than 1% per year) when used            │ celiac disease, Wegner's granulomatosis, active    │         │
│ consistently and correctly. Note that some         │ Hashimoto's thyroiditis, rheumatoid arthritis,     │         │
│ contraception methods were not considered highly   │ lupus, scleroderma and its variants, multiple      │         │
│ effective (e.g., male or female condom with or     │ sclerosis, myasthenia gravis). Vitiligo, type I    │         │
│ without spermicide; female cap, diaphragm, or      │ diabetes mellitus, residual hypothyroidism due to  │         │
│ sponge with or without spermicide; non-copper      │ autoimmune condition only requiring hormone        │         │
│ containing intrauterine device; progestogen-only   │ replacement, psoriasis not requiring systemic      │         │
│ oral hormonal contraceptive pills where inhibition │ treatment, or conditions not expected to recur in  │         │
│ of ovulation is not the primary mode of action     │ the absence of an external trigger are permitted   │         │
│ \[excluding Cerazette/desogestrel which is         │                                                    │         │
│ considered highly effective\]; and triphasic       │                                                    │         │
│ combined oral contraceptive pills)                 │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ Age ≥18 years                                      │      43 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Aspartate aminotransferase (AST)/alanine           │ Alkaline phosphatase: ≤ 2.5 x ULN                  │      46 │
│ aminotransferase (ALT): ≤ 2.5 x ULN                │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Eastern Cooperative Oncology Group (ECOG)          │ ECOG performance status of 0 or 1                  │      64 │
│ performance status of 0 or 1                       │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior exposure to doxorubicin, PLD or any other    │ Prior exposure to doxorubicin, PLD or any other    │      70 │
│ anthracycline, motolimod and other toll-like       │ anthracycline, motolimod and other TLR agonists,   │         │
│ receptor agonists, durvalumab or checkpoint        │ MEDI4736 or checkpoint inhibitors, such as anti-   │         │
│ inhibitors, such as anti-cytotoxic T-lymphocyte-   │ CTLA4 and anti-PD1/anti-PD-L1 antibodies           │         │
│ associated antigen-4 (CTLA-4) and anti-programmed  │                                                    │         │
│ cell death-1 (PD-1)/anti-programmed cell death     │                                                    │         │
│ ligand-1 (PD-L1) antibodies                        │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ one additional cytotoxic regimen and/or poly       │ one additional cytotoxic regimen and/or PARP       │      81 │
│ adenosine diphosphate-ribose polymerase inhibitor  │ inhibitor for management of recurrent or           │         │
│ for management of recurrent or persistent disease  │ persistent disease                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Baseline ejection fraction ≤ 50% as assessed by    │ Baseline ejection fraction ≤ 50% as assessed by    │      81 │
│ echocardiogram or multiple-gated acquisition       │ echocardiogram or MUGA                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known immunodeficiency or human immunodeficiency   │ Known immunodeficiency or HIV, Hepatitis B or      │      81 │
│ virus, Hepatitis B or Hepatitis C positivity       │ Hepatitis C positivity                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female subjects should have refrained from         │ -Female subjects should refrain from breastfeeding │      84 │
│ breastfeeding throughout the period described      │ throughout this period                             │         │
│ above                                              │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒═══════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Female subjects should have refrained from        │ Women who are breastfeeding or pregnant as         │      46 │
│ breastfeeding throughout the period described     │ evidenced by positive serum pregnancy test         │         │
│ above                                             │                                                    │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Able and willing to give valid written informed   │ Subjects unwilling to use acceptable methods of    │      52 │
│ consent                                           │ contraception                                      │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Alkaline phosphatase: ≤ 2.5 x ULN                 │ AST/ALT: ≤ 2.5 x ULN                               │      53 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Eastern Cooperative Oncology Group (ECOG)         │ ECOG performance status of 0 or 1                  │      64 │
│ performance status of 0 or 1                      │                                                    │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior exposure to doxorubicin, PLD or any other   │ Prior exposure to doxorubicin, PLD or any other    │      70 │
│ anthracycline, motolimod and other toll-like      │ anthracycline, motolimod and other TLR agonists,   │         │
│ receptor agonists, durvalumab or checkpoint       │ MEDI4736 or checkpoint inhibitors, such as anti-   │         │
│ inhibitors, such as anti-cytotoxic T-lymphocyte-  │ CTLA4 and anti-PD1/anti-PD-L1 antibodies           │         │
│ associated antigen-4 (CTLA-4) and anti-programmed │                                                    │         │
│ cell death-1 (PD-1)/anti-programmed cell death    │                                                    │         │
│ ligand-1 (PD-L1) antibodies                       │                                                    │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ one additional cytotoxic regimen and/or poly      │ one additional cytotoxic regimen and/or PARP       │      81 │
│ adenosine diphosphate-ribose polymerase inhibitor │ inhibitor for management of recurrent or           │         │
│ for management of recurrent or persistent disease │ persistent disease                                 │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Baseline ejection fraction ≤ 50% as assessed by   │ Baseline ejection fraction ≤ 50% as assessed by    │      81 │
│ echocardiogram or multiple-gated acquisition      │ echocardiogram or MUGA                             │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known immunodeficiency or human immunodeficiency  │ Known immunodeficiency or HIV, Hepatitis B or      │      81 │
│ virus, Hepatitis B or Hepatitis C positivity      │ Hepatitis C positivity                             │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female subjects should have refrained from        │ -Female subjects should refrain from breastfeeding │      84 │
│ breastfeeding throughout the period described     │ throughout this period                             │         │
│ above                                             │                                                    │         │
╘═══════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 74
Average Levenshtein Ratio of individual lines: 81.828125
OverAll Ratio: 77.9140625
